Proteomic profiling to predict therapeutic response to anti-PD1 therapy in advanced melanoma – SWATH MS dataset - glycopeptides

ABSTRACT: MS-based proteomics based on data-independent acquisition / SWATH MS was used to study the response of melanoma patients to anti-PD1 therapy. Human serum samples were collected from patients at the start of their therapy and later categorized into responders and non-responders based on clinical outcome. Samples were subjected to glycocapture and glycopeptides were quantified by SWATH MS followed by analysis using mapDIA to protein levels.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Serum

DISEASE(S): Melanoma

SUBMITTER: Ludovic Gillet  

LAB HEAD: Ruedi Aebersold

PROVIDER: PXD027933 | Pride | 2023-08-21

REPOSITORIES: Pride